Genfit (FRA:XUPB) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:XUPB Genfit SA FRA:XUPB
59 GF Score
Price €6.15
GF Value €4.06
! 10 Warning Signs
View Full Analysis

What is Genfit Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:XUPB
59GF Score
Genfit SA FRA:XUPB
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genfit (FRA:XUPB) Overvalued in 2026?

Based on GuruFocus' analysis, Genfit stock appears to be overvalued. The current stock price of €6.15 is trading 51.5% above its estimated GF Value™ of €4.06.

Key valuation signals for FRA:XUPB:

  • Short Ratio:
  • GF Value™: €4.06 vs. price of €6.15 (51.5% above fair value)
  • GF Score™: 59/100 with 10 warning signs

No single metric tells the full story. See the FRA:XUPB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genfit Business Description

Address 885, Avenue Eugene Avinee, Parc Eurasante, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
59GF Score

Get the complete analysis for FRA:XUPB

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.15
Price
€4.06
GF Value